TWI799896B - 多雜環小分子藥物偶合物及其用途 - Google Patents

多雜環小分子藥物偶合物及其用途 Download PDF

Info

Publication number
TWI799896B
TWI799896B TW110122317A TW110122317A TWI799896B TW I799896 B TWI799896 B TW I799896B TW 110122317 A TW110122317 A TW 110122317A TW 110122317 A TW110122317 A TW 110122317A TW I799896 B TWI799896 B TW I799896B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical uses
heterocyclic conjugates
poly heterocyclic
poly
conjugates
Prior art date
Application number
TW110122317A
Other languages
English (en)
Other versions
TW202210491A (zh
Inventor
鄒倫
黃冠勳
陳炯東
全 石
Original Assignee
財團法人國家衛生研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 財團法人國家衛生研究院 filed Critical 財團法人國家衛生研究院
Publication of TW202210491A publication Critical patent/TW202210491A/zh
Application granted granted Critical
Publication of TWI799896B publication Critical patent/TWI799896B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
TW110122317A 2020-06-22 2021-06-18 多雜環小分子藥物偶合物及其用途 TWI799896B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063042276P 2020-06-22 2020-06-22
US63/042,276 2020-06-22

Publications (2)

Publication Number Publication Date
TW202210491A TW202210491A (zh) 2022-03-16
TWI799896B true TWI799896B (zh) 2023-04-21

Family

ID=79032425

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110122317A TWI799896B (zh) 2020-06-22 2021-06-18 多雜環小分子藥物偶合物及其用途

Country Status (12)

Country Link
US (1) US11878986B2 (zh)
EP (1) EP4168005A1 (zh)
JP (1) JP2023531656A (zh)
KR (1) KR20230027100A (zh)
CN (1) CN116528858A (zh)
AU (1) AU2021296282A1 (zh)
BR (1) BR112022026295A2 (zh)
CA (1) CA3181686A1 (zh)
MX (1) MX2022016456A (zh)
TW (1) TWI799896B (zh)
WO (1) WO2021262628A1 (zh)
ZA (1) ZA202212959B (zh)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179299A1 (en) * 2014-05-22 2015-11-26 Molecular Targeting Technologies, Inc. Dipicolylamine derivatives and their pharmaceutical uses

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104984360A (zh) 2009-06-03 2015-10-21 伊缪诺金公司 轭合方法
US9566355B2 (en) 2013-03-13 2017-02-14 Northwestern University Bacteria-targeted magnetic resonance contrast agents
CN116440279A (zh) 2015-09-17 2023-07-18 伊缪诺金公司 包含抗folr1免疫缀合物的治疗组合

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015179299A1 (en) * 2014-05-22 2015-11-26 Molecular Targeting Technologies, Inc. Dipicolylamine derivatives and their pharmaceutical uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
網路文獻 Reddy JA, et al. Folate receptor-specific antitumor activity of EC131, a folate-maytansinoid conjugate Cancer Res., Vol. 67(13), 2007, pages 6376-6382 *

Also Published As

Publication number Publication date
BR112022026295A2 (pt) 2023-01-17
US11878986B2 (en) 2024-01-23
MX2022016456A (es) 2023-02-01
CN116528858A (zh) 2023-08-01
TW202210491A (zh) 2022-03-16
AU2021296282A1 (en) 2023-01-05
KR20230027100A (ko) 2023-02-27
US20210403483A1 (en) 2021-12-30
EP4168005A1 (en) 2023-04-26
ZA202212959B (en) 2024-05-30
WO2021262628A1 (en) 2021-12-30
JP2023531656A (ja) 2023-07-25
CA3181686A1 (en) 2021-12-30

Similar Documents

Publication Publication Date Title
EP4032892A4 (en) CAMPTOTHECIN DERIVATIVE AND CONJUGATE THEREOF
EP3981434A4 (en) ANTI-B7-H4 ANTIBODY-DRUG CONJUGATE AND RELATED MEDICAL USE
EP3797796A4 (en) ANTIBODY INGREDIENT CONJUGATES AND USES THEREOF
EP3958910A4 (en) ANTI-CD45-DRUG ANTIBODY CONJUGATES AND THEIR USES
IL189187A (en) Polymeric couplings of a252-k and their history, their pharmaceutical preparations and their uses
EP3903825A4 (en) DRUG-LIGAND CONJUGATE AND USE THEREOF
EP4074345A4 (en) ANTI-CLAUDINE ANTIBODY-DRUG CONJUGATE AND ITS PHARMACEUTICAL USE
EP3873931A4 (en) Anti-cd79b antibodies, drug conjugates, and applications thereof
EP4149470A4 (en) PHARMACEUTICAL FORMULATIONS AND USES THEREOF
EP4043034A4 (en) LYSOSOME TARGETING ANTIBODY-DRUG CONJUGATE AND USE THEREOF
EP4183391A4 (en) PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP4211145A4 (en) EXATECAND DERIVATIVES, LINKER PAYLOADS AND CONJUGATES AND THEREOF
EP4103539A4 (en) COMPOUNDS AND PHARMACEUTICAL USES THEREOF
EP3972647A4 (en) DRUG CONJUGATES AND METHODS OF USE
EP4101860A4 (en) HYALURONIC ACID DERIVATIVES, PHARMACEUTICAL COMPOSITION AND HYALURONIC ACID DERIVATIVES-INGREDIENT CONJUGATE
EP4134366A4 (en) 3-AZABICYCLOALKYL DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
EP3941946A4 (en) CLAUDIN-6 ANTIBODIES AND DRUG CONJUGATES
EP4129335A4 (en) ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
EP4129402A4 (en) HYDROXYPYRROLIDINE DERIVATIVE AND MEDICAL USE THEREOF
TWI799896B (zh) 多雜環小分子藥物偶合物及其用途
EP3976019A4 (en) HYALURONAN CONJUGATES AND USES THEREOF
EP3666788A4 (en) HEMIASTERLIN DERIVATIVES AND ANTIBODY-ACTIVE INGREDIENT CONJUGATES CONTAINING THESE
EP4230205A4 (en) ANTITUMOR DRUG COMPOSITION AND USE THEREOF
EP4180040A4 (en) PHARMACEUTICAL COMPOSITION AND ITS APPLICATION
EP4140480A4 (en) DRUG COMBINATION AND USE